about
Treating Metastatic Breast Cancer: The Evidence for Targeted TherapyFulvestrant for hormone-sensitive metastatic breast cancerChemotherapy, surgery and radiotherapy for locally advanced breast cancerLarger versus smaller dose of the same drug/s regimen for metastatic breast cancerCombination versus sequential single agent chemotherapy for metastatic breast cancerPost-operative radiotherapy for ductal carcinoma in situ of the breastCombination versus sequential single agent chemotherapy for metastatic breast cancerAddition of drug/s to a chemotherapy regimen for metastatic breast cancerPost-operative radiotherapy for ductal carcinoma in situ of the breastPost-operative radiotherapy for ductal carcinoma in situ of the breastPost-operative radiotherapy for ductal carcinoma in situ of the breastSingle agent versus combination chemotherapy for metastatic breast cancerPost-operative radiotherapy for ductal carcinoma in situ of the breastTaxanes for adjuvant treatment of early breast cancerSingle agent versus combination chemotherapy for metastatic breast cancerAddition of drug/s to a chemotherapy regimen for metastatic breast cancerAntitumour antibiotic containing regimens for metastatic breast cancerLarger versus smaller dose of the same drug/s regimen for metastatic breast cancerDuration of chemotherapy for metastatic breast cancerTaxane containing regimens for metastatic breast cancerPlatinum containing regimens for metastatic breast cancerChemotherapy, surgery and radiotherapy for locally advanced breast cancerChemotherapy alone versus endocrine therapy alone for metastatic breast cancerHigh dose, high risk? What updated evidence tells us about chemotherapy dosing in early breast cancer
P50
Q24193683-295EF524-64DF-4E29-9985-48F2BB899A85Q24194916-9FF71D6A-662A-488E-A46B-2722E27F2DC9Q24194935-476E4286-176D-49B4-A46E-05360CA23FBAQ24194953-0C0F477C-D22D-4853-8BF2-81E4FF5723D1Q24201726-F39017CC-1E9D-4E7A-9F58-659098788C0DQ24202386-70D7793E-8181-49DE-9899-2ACD048B6D7FQ24234874-3C630144-A3CF-4AB1-9943-B4BC8D7EEA18Q24236594-5FB658F3-2F25-4682-A5CA-691699062B42Q24240098-B5C26373-D365-4065-8B78-886E18A87151Q24240332-86871D3B-3680-46F6-8A97-F9A87667BFA4Q24240999-7B813A42-054E-49D5-8A82-875E4C5E05D2Q24241459-05C7E001-8B82-45C2-B500-1DE6B3D1F9E2Q24242673-5A816B16-D174-4056-9DF5-AB8D9365D80CQ24242987-7EB5DF51-9B26-4327-A74C-E0231BDA33A2Q24244200-BADF964F-4155-4E81-A188-C047D3D99C21Q24245443-D7F244BC-8CA9-4511-81D6-B99BD5D5D81EQ24245647-3A99881E-D010-44AB-946D-B137A9859871Q24246116-34550BD9-6FEA-4408-8D6C-03AF1C4AD230Q24246859-53EFF600-BF0F-423B-8422-4F37181573D8Q24246978-04A68BB8-AC43-42D7-BA6B-0C06ED11C8E5Q24247134-A24AB1DC-A7A0-4358-BCA5-D984173A28C3Q24248150-4C15A21F-0AE4-490A-A03C-409735F27265Q24248696-96D09AEC-476D-4934-8C0F-F89ECAF41D8CQ26471855-E957855F-92AC-4E90-B579-03CD1BCDD8EE
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Nicholas Wilcken
@ast
Nicholas Wilcken
@en
Nicholas Wilcken
@es
Nicholas Wilcken
@nl
Nicholas Wilcken
@sl
type
label
Nicholas Wilcken
@ast
Nicholas Wilcken
@en
Nicholas Wilcken
@es
Nicholas Wilcken
@nl
Nicholas Wilcken
@sl
prefLabel
Nicholas Wilcken
@ast
Nicholas Wilcken
@en
Nicholas Wilcken
@es
Nicholas Wilcken
@nl
Nicholas Wilcken
@sl